Oral therapy of NSAIDs for treatment of rheumatoid arthritis causes gastric irritation and ulceration. In the present study transdermal patch of ketoprofen was developed using hydroxyl propyl methyl cellulose E5 and Eudragit S100. Patches were prepared by solvent evaporation method. Optimization was carried out by 32 factorial design with polymer concentration (HPMC E5) and plasticizer concentration (propylene glycol) as independent variables. Patches were evaluated for folding endurance, surface pH, drug content, percent moisture content, water uptake and swelling studies. Ex vivo permeation studies of optimized patch was performed using Franz diffusion cell while bioadhesion force and tensile strength were measured by using texture analyzer. Hydrophilic nature, swelling ability and wettability of polymer and plasticizer were responsible for increase in flux and bioadhesion with increase in their concentrations in the factorial batches. Swelling index of all formulations was in the range of 17.3 ±1.2 to 65.29 ±4.78 up to 3h. Flux obtained from all batches was in the range of 3.37±0.23 to 5.43±0.13µg/h/cm2. Anti-inflammatory studies using carrageenan-induced rat paw edema showed greater paw swelling reduction in case of ketoprofen patch. Cumulative percent drug permeation of optimized patch through nylon 66, Wistar rat skin and cadaver skin was found to be 92.3% >86.28 %>63.42% in 8h, while flux order was 6.073> 5.442 > 2.219 µg/h/cm2 respectively. The study concludes that transdermal patch of ketoprofen will be more efficacious with absence of gastric irritation observed in oral formulations. Keywords: Ketoprofen, Bioadhesion, HPMC E5, Flux, Backing membrane

Liquisolid technology is very effective technique for improving the solubility and dissolution properties of poorly water soluble drug formulations like Clotrimazole. Clotrimazole is a BCS Class II, antifungal drug used for treatment for Vaginal Candidiasis.  In this liquisolid technique the drug soluble in non volatile solvents and then it converted into free flowing, non adherent powder, which can be compressed into tablet. Here N-methyle-2-pyrrolidone and propylene glycol is used in the ratio of 1:1 as a solvent. Neusilin US2 and Aerosil 200 used as Coating and Carrier material respectively. For mucoadhesion on vaginal wall Sodium carboxymethyle cellulose used as a mucoadhesive agent. Mucoadhesive tablets were prepared using direct compression technique. Magnesium Stearate used as a glidant. Mucoadhesive liquisolid tablets were evaluated as precompression evalutions and post compression evaluations. Future tablets were evaluated as In vitro and Ex vivo evaluations. The optimized batch showed that In vitro release in simulated vaginal fluid pH 4.5 in 6 hr was 99%. Ex vivo diffusion studies of optimized batch showed 80% of drug diffusion in 6 hr. Mucoadhesive strength showed high mucoadhesion of optimized batch that is 36 gm. From this study it was concluded that liquisolid technology is an effective technique to improve solubility and dissolution properties of poorly water soluble drug formulations like Clotrimazole.